Fresh2 Group Limited

Equities

FRES

US03635R2067

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.5787 ^USD	-3.55%		+57.13%	-34.98%

Apr. 22	Fresh2 Group Receives Nasdaq Notice of Non-Compliance	MT
Mar. 21	ADRs Edge Higher; Lufax Climbs Almost 46%	DJ

Fresh2 Group Limited announced that it has received $13.512496 million in funding

March 18, 2024

On March 19, 2024, Fresh2 Group Limited closed the transaction. The company announced it has issued all of the additional 46,328,557 Class A ordinary shares at issue price of 0.175 per share for a gross proceeds $8,107,497.475 in its third tranche.

Latest news about Fresh2 Group Limited

Fresh2 Group Receives Nasdaq Notice of Non-Compliance	Apr. 22	MT
ADRs Edge Higher; Lufax Climbs Almost 46%	Mar. 21	DJ
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	Mar. 19	DJ
Fresh2 Group Limited announced that it has received $13.512496 million in funding	Mar. 18	CI
ADRs End Flat, Fresh2 Group Ltd. Climbs 47.7%	Mar. 18	DJ
Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and Consumers	Feb. 20	CI
ADRs Close Higher; Airnet Technology Climbs 54%	Feb. 15	DJ
Dollar slides versus yen as Japan warns against rapid fall	Feb. 14	RE
JGB yields track US peers up as investors weigh weak yen's impact on BOJ path	Feb. 14	RE
Dollar reigns as hot inflation cools Fed cut bets	Feb. 14	RE
Dollar reigns supreme as hot CPI cools bets for Fed cuts	Feb. 13	RE
ADRs Close Lower, Polestar Automotive Holding UK PLC Wt Declines 35.3%	Feb. 13	DJ
ADRs End Higher; Morphosys Climbs 56%	Feb. 05	DJ
Stocks strong, yields dip, this week's excitement still to come	Jan. 29	RE
ADRs End Lower; Evaxion Biotech A/S Drops 45%	Jan. 22	DJ
ADRs End Higher; The9 Climbs 16%	Jan. 19	DJ
ADRs End Lower, WISekey International Holding Ltd. Declines 17.3%	Jan. 17	DJ
ADRs Hold Steady; TDCX Inc. Climbs 30.4%	Jan. 03	DJ
ADRs Slump; FLJ Group Declines 21%	Jan. 02	DJ
ADRs Advance; Earlyworks Co. Ltd. Climbs 69.3%	Dec. 27	DJ
Fresh2 Group Limited Appoints Zhijun Liang as Independent Director, Effective January 1, 2024	Dec. 15	CI
UK's FTSE 100 hits over two-week high as miners shine	Dec. 01	RE
ADRs Slump, Connect Biopharma Holdings Ltd. Declines 38.8%	Nov. 21	DJ
Dollar poised to halt slide after Fed minutes	Nov. 21	RE
Euro zone bonds hold steady as ECB officials push back on early rate cut bets	Nov. 21	RE

Chart Fresh2 Group Limited

Duration

Period

More charts

Company Profile

AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
FRESH2 GROUP LIMITED	-34.98%	12.86M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing